Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations - Reply

被引：1

作者：

Cho, Byoung Chul ^{[1
,2
,3
]}

Kim, Joo Hang ^{[1
,2
,3
]}

机构：

[1] Yonsei Canc Ctr, Seoul, South Korea

[2] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[3] Yonsei Univ, Med Ctr, Lung Canc Clin Severance Hosp, Seoul 120749, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 07期

关键词：

D O I：

10.1200/JCO.2007.14.9351

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1184 / 1186

页数：4

共 15 条

[1] HER3 and mutant EGFR meet MET [J].

Arteaga, Carlos L. .

NATURE MEDICINE, 2007, 13 (06) :675-677

[2] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[3] Erlotinib response EGFR-mutant gefitinib-resistant non-small-cell lung cancer [J].

Chang, John Wen-Cheng ;

Chou, Chun-Liang ;

Huang, Shiu-Feng ;

Wang, Hung-Ming ;

Hsieh, Jia-Juan ;

Hsu, Todd ;

Cheung, Yun-Chung .

LUNG CANCER, 2007, 58 (03) :414-417

[4] Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib [J].

Cho, Byoung Chul ;

Im, Chong-Kun ;

Park, Moo-Suk ;

Kim, Se Kyu ;

Chang, Joon ;

Park, Jong Pil ;

Choi, Hye Jin ;

Kim, Yu Jin ;

Shin, Sang-Joon ;

Sohn, Joo Hyuk ;

Kim, Hoguen ;

Kim, Joo Hang .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) :2528-2533

[5] Case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma [J].

Garfield, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7738-7740

[6] Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer [J].

Gridelli, Cesare ;

Maione, Paolo ;

Galetta, Domenico ;

Colantuoni, Guiseppe ;

Del Gaizo, Filomena ;

Ferrara, Carmine ;

Guerriero, Ciro ;

Nicolella, Dario ;

Rossi, Antonio .

JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :758-761

[7] Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia [J].

Kantarjian, HM ;

Talpaz, M ;

O'Brien, S ;

Giles, F ;

Garcia-Manero, G ;

Faderl, S ;

Thomas, D ;

Shan, JQ ;

Rios, MB ;

Cortes, J .

BLOOD, 2003, 101 (02) :473-475

[8] Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer [J].

Kimura, Hideharu ;

Kasahara, Kazuo ;

Kawaishi, Makoto ;

Kunitoh, Hideo ;

Tamura, Tomohide ;

Holloway, Brian ;

Nishio, Kazuto .

CLINICAL CANCER RESEARCH, 2006, 12 (13) :3915-3921

[9] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].

Kobayashi, S ;

Boggon, TJ ;

Dayaram, T ;

Janne, PA ;

Kocher, O ;

Meyerson, M ;

Johnson, BE ;

Eck, MJ ;

Tenen, DG ;

Halmos, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792

[10] Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib [J].

Kwak, EL ;

Sordella, R ;

Bell, DW ;

Godin-Heymann, N ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Driscoll, DR ;

Fidias, P ;

Lynch, TJ ;

Rabindran, SK ;

McGinnis, JP ;

Wissner, A ;

Sharma, SV ;

Isselbacher, KJ ;

Settleman, J ;

Haber, DA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (21) :7665-7670

← 1 2 →